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Available online 7 June 2017Although inﬂiximab (IFX) is an efﬁcient therapy for ulcerative colitis (UC) patients, a considerably high rate of
therapeutic failures still occurs. This study aimed at a better understanding of IFX pharmacokinetics and pharma-
codynamics among clinically-asymptomatic UC patients. Thiswas amulticentric and prospective study involving
65 UC patients in the maintenance phase of IFX therapy. There were no signiﬁcant differences between patients
with positive and negative clinical, endoscopic and histological outcomes concerning their IFX trough levels
(TLs), area under the IFX concentration vs. time curve (AUC), clearance and antibodies to inﬂiximab (ATI) levels.
However, the need to undergo therapeutic escalation later in disease development was signiﬁcantly associated
with higher ATI levels (2.62 μg/mL vs. 1.15 μg/mL, p= 0.028). Moreover, and after adjusting for disease severity,
the HR (hazard ratio) for therapeutic escalation was signiﬁcantly decreased for patients with an ATI concentra-
tion below 3 μg/mL (HR = 0.119, p = 0.010), and increased for patients with fecal calprotectin (FC) level
above 250 μg/g (HR = 9.309, p = 0.018). In clinically-stable UC patients, IFX pharmacokinetic features cannot
predict therapeutic response on a short-term basis. However, high levels of ATIs or FC may be indicative of a fu-
ture therapeutic escalation.gy and
. This i© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Ulcerative colitis
Antibodies to inﬂiximab
Fecal calprotectin
Therapeutic escalationTherapeutics, Faculty of Medicine, University of Porto, Alameda Prof. Hernâni Monteiro, 420-319 Porto, Portugal.
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124 F. Magro et al. / EBioMedicine 21 (2017) 123–1301. IntroductionThe knowledge of the crucial role played by the tumor necrosis fac-
tor α (TNFα) on the pathophysiology of auto-immune inﬂammatory
disorders, such as inﬂammatory bowel diseases (IBD), led to the devel-
opment of a class of biological drugs that target this cytokine. Inﬂiximab
(IFX)was the ﬁrst anti-TNFα approved for the treatment of IBD (Danese
et al., 2015). Since its introduction, IBD patients experienced an im-
provement in their quality of life, a decrease on the number of bowel-re-
lated surgeries and hospitalizations, and an increase in steroid-free
remission and mucosal healing rates (Gecse et al., 2016; Strik et al.,
2016). Notwithstanding, and despite the therapeutic success of these bi-
ological drugs, some patients fail to respond to anti-TNFα in the induc-
tion period (primary non-responders), whereas others initially beneﬁt
from the treatment but eventually loose response (secondary non-re-
sponders) (Mould et al., 2016). Immunogenicity, i.e., the development
of anti-drug antibodies, is an unavoidable drawback of biological treat-
ments and a possible explanation for the lack or loss of response. Anti-
bodies to inﬂiximab (ATIs) can directly neutralize the IFX effects by
interfering with the TNFα-binding domain, or can affect the drug's
clearance rate by forming immune complexes with IFX, thereby pro-
moting its removal from the circulating system (Gecse et al., 2016).
Therapeutic drug monitoring (TDM)-based dosing is an interesting
and efﬁcient strategy to overcome IFX lack or loss of response. In
order to establish an accurate algorithm to support the decision-making
process on a TDM approach, many studies have attempted to elucidate
IFX pharmacokinetics and to deﬁne therapeutic thresholds for IFX expo-
sure (often using serum trough levels [TLs] as a proxy) and for ATI levels
that can guide dose adjustments (Strik et al., 2016; Moore et al., 2016;
Williet et al., 2016; Vande Casteele et al., 2015; Warman et al., 2015;
Paul et al., 2013; Cornillie et al., 2014).
In parallel with drug monitoring, disease monitoring through non-
invasive biomarkers plays an important role in IBD patients, as it allows
an assessment of the inﬂammatory burdenwithout the risks involved in
colonoscopy-related procedures. Calprotectin constitutes up to 60% of
the cytosolic protein content in granulocytes, and its presence in feces
reﬂects the migration of neutrophils through the inﬂamed bowel wall
to the mucosa (Gisbert andMcNicholl, 2009). Recent evidences suggest
that fecal calprotectin (FC) levels can be used to discriminate organic
from functional disease, to assess disease activity and response to ther-
apy, and to predict relapses (Benítez and García-Sánchez, 2015).
This study aimed to explore IFX pharmacodynamics and to assess
the utility of monitoring drug and FC levels among a speciﬁc population
of ulcerative colitis (UC) patients: those that are asymptomatic and con-
sidered to be in remission according to the Montreal classiﬁcation. The
main goal of this study was thus to deﬁne how useful – from a clinical
point of view – is the monitoring drug, anti-drug antibodies and disease
biomarker's levels in clinically-stable patients.
2. Material and Methods
2.1. Patients
UC patients in themaintenance phase of IFX therapy - 5 mg/kg infu-
sions every six or eight weeks - were prospectively and consecutively
recruited from 10 different hospitals. Only patients older than
18 years, with at least 14 weeks of IFX treatment and in remission ac-
cording to theMontreal classiﬁcation (at baseline and at least in the im-
mediately previous consultation)were invited to participate. Moreover,
all patients were in their regimens (6 or 8 weeks-interval infusions) for
at least three infusions, to ensure stability. The decision of enrolling
these patients in biological therapy had been done previously by the at-
tending physician, following an inadequate response to AZA (azathio-
prine) or 6-MP (6-mercaptopurine) after a period of treatment equal
or superior to three months, intolerance to these agents, or a severe
acute relapse. Patients in the 6-weeks infusion interval had beeninitially allocated to the 8-weeks regimen, but were empirically placed
in the shorter interval due to loss of response (LOR). Previously deﬁned
concomitant medication was maintained (dose and regimen) through-
out the entire study. Exclusion criteria included patients with proctitis
only; history of malignancy in the previous ﬁve years, opportunistic in-
fections or demyelinating diseases; existence of adenomatous polyps or
known viral infections; pregnancy and breastfeeding; and use of topical
treatment (5-ASA or steroids) during the study period or in the previous
month.
This study was approved by the ethic committee of all hospitals in-
volved and by the Portuguese Data Protection Authority (Comissão
Nacional de Protecção deDados). All patients enrolled did so voluntarily
and after signing a written informed consent. The national coordinator
of the Portuguese IBD group (GEDII – Grupo de Estudo de Doenças
Inﬂamatórias Intestinais) monitored the study.
2.2. Study Design
This was a multicentric and prospective observational study. All pa-
tients were closely monitored for six or eight weeks after an IFX infu-
sion. Demographic and baseline characteristics were collected before
the infusion (T = 0), whereas histological, endoscopic and clinical out-
comes were assessed immediately before the following infusion (T =
42 or 56 days). IFX and ATIs were quantiﬁed 2 h and 14 days after the
initial infusion, as well as immediately before the following one (T =
42 or 56 days). The different assessments and their timings are depicted
in Fig. 1.
2.2.1. IFX and ATI Quantiﬁcation
The levels of IFX were quantiﬁed using an in-house ELISA assay, as
previously described by Ben-Horin et al. (Ben-Horin et al., 2011). The
presence and amount of ATIs were assessed using the anti-human
lambda chain assay (AHLC), an in-house ELISA procedure also described
by Ben-Horin et al. (Ben-Horin et al., 2011). The ATI concentrations are
expressed in μg/mL-equivalent, hereafter referred to as μg/mL for the
purpose of brevity. The concentration of IFX at each time point was
used to construct a concentration vs. time curve. The area under the
curve (AUC) was calculated for each individual using the Linear Up/
Log Down Trapezoidal method, whereas clearance was computed as
the total IFX dose per patient divided by the correspondent AUC.
2.2.2. Endoscopic Activity
Endoscopic activity was evaluated using Ulcerative Colitis Endoscopic
Index of Severity (UCEIS) (Travis et al., 2012), and the presence of
macroscopic lesions was assessed with the Mayo endoscopic sub-
score (Schroeder et al., 1987). Patients were considered to be in en-
doscopic remission whenever UCEIS was below 2, whereas mucosal
healing was deﬁned as a Mayo endoscopic sub-score either equal to
0 or lower than 2.
2.2.3. Histological Activity
To assess the presence of histological inﬂammation, an average of
two samples per localization was collected from the sigmoid and rec-
tum. Histological activity was evaluated following the Geboes score
(Geboes et al., 2000), and histological remission was deﬁned as a
Geboes index lower than 3.1. All samples were the subject of a central
reading by two independent pathologists blinded to the patients' dis-
ease status and endoscopic results. Disagreements between patholo-
gists were resolved by a review including a third pathologist (K.
Geboes) and using a multiheaded microscope, deﬁning the ﬁnal score.
2.2.4. Clinical Remission
Clinical remissionwas evaluated according to theGlobalMayo score.
Patients were considered to be in clinical remission if their global Mayo
score was below or equal to 2 and no individual sub-score was above 1.
Fig. 1. IFX levels variation throughout time in patients on the 6-weeks (A) or the 8-weeks (B) schedule. The different assessments made during this study and their timing is indicated in
the time bar.
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Stool samples were collected and kept at 4 °C (for a maximum of
48 h) until shipment to the central laboratory (Department of Pharma-
cology and Therapeutics, Faculty of Medicine of University of Porto). FC
was extracted from stools within amaximum of seven days after collec-
tion using the ‘Fecal sample preparation kit’ (Roche Diagnostics, Germa-
ny) according to the instructions provided by the manufacturer and
stored at −80 °C until quantiﬁcation. FC samples were quantiﬁed
using a ﬂuoroenzyme immunoassay (EliA Calprotectin®, Thermo Fisher
Scientiﬁc, Germany) according with manufacturers' instructions.2.2.6. Assessment of Therapeutic Escalation
The ﬁles of all patients included in this study were later assessed in
order to evaluate howmany required therapeutic escalation. Therapeu-
tic escalation was deﬁned as has been previously suggested (Kalla et al.,
2016), and included the presence of at least one of the following events:
starting a new immunomodulator or biological drug; switching immu-
nomodulator; increasing biological dosage or shortening infusion inter-
val; switching biological drug due to LOR; need to undergo bowel-
related surgery.Table 1
Cohort characterization.
n %
Gender
Male 28 43.1
Female 37 56.9
Smoking status
Never smoked 42 68.9
Former smoker 15 24.6
Smoker 4 6.6
Location of disease
Left-side colitis 33 50.8
Extensive colitis 32 49.2
Extra-intestinal manifestations 16 26.2
Azathioprine 44 67.7
Azathioprine intolerant 10 16.1
Steroids 7 10.8
Corticodependent 39 60.9
Corticoresistent 12 18.52.3. Statistical Analysis
Categorical variables were described through absolute (n) and rela-
tive (%) frequencies and continuous variables were described as mean
and standard deviation, median, interquartile range (IQR), and mini-
mum/maximum values, whenever appropriate. When testing hypothe-
sis concerning continuous variables, nonparametric Kruskall Wallis
tests were used as appropriate, taking into account normality assump-
tions and the number of groups compared. In order to have amore thor-
ough understanding of the factors associated with clearance, univariate
and multivariate logistic regression modelling were used. The time
elapsed from assessment to therapeutic escalation was evaluated
using survival analysis. To determine the factors associated to therapeu-
tic escalation, Cox regression was used. The cumulative probabilities of
event-free survival were estimated with the Kaplan-Meier method
using log-rank and Breslow tests. The reported p values were two-
sided, and p values below 0.05were considered to be statistically signif-
icant. The cut-offs used to stratify the outcomes concerning IFX trough
levels, clearance, and ATI levels were chosen based on the literature
(Afonso et al., 2016; Vande Casteele et al., 2015). All data was arranged,
processed and analyzed with SPSS® v.20.0 data (Statistical Package for
Social Sciences), whereas graphs were designed using Prism 6.3. Results
3.1. Characterization of the Cohort
The cohort analyzed in this study included 65 UC patients in remis-
sion being treated with 5 mg/kg IFX every six weeks (n= 21, 32.3%) or
every eight weeks (n = 44, 67.7%) (Table 1). Overall, most patients
were female (56.9%) and had never smoked (68.9%). The location of
the disease was distributed as follows: 50.8% of the patients had left-
side and 49.2% patients had extensive colitis. Concerning concomitant
therapies, 67.7% of the patients were or had been on AZA, whereas
10.8%were or had been taking steroids. Therewere no signiﬁcant differ-
ences between the baseline characteristics of the patients doing the 6-
weeks' and the 8-weeks' regimen (data not shown).
3.2. Pharmacokinetics
Patientswere followed during one IFX infusion cycle, and the assess-
ments made throughout time are illustrated in Fig. 1. The IFX trough
levels (TLs) were signiﬁcantly higher in the patients enrolled in
the 6-weeks' regimen when compared to those in the 8-weeks'
one: median TL6 weeks = 5.00 μg/mL, IQR: 2.68–9.60 vs. median
TL8 weeks = 2.43 μg/mL, IQR: 0.91–3.70, p = 0.006. However, there
was no signiﬁcant difference between the two regimens concerning
the ATI concentration (median ATI6 weeks = 1.15 μg/mL, IQR: 0.88–
2.48 vs. median ATI8 weeks = 1.51 μg/mL, IQR: 0.80–2.18, p = 0.592),
Table 3
Regression analyses of the clearance rate (mL/day).
Variables OR 95% CI p-Value
Height (m) 413.589 −127.938; 955.115 0.130
Weight (kg) 1.028 −1.483; 3.539 0.411
Albumin 0.758 −6.114; 7.630 0.824
[ATI] μg/mL 12.210 2.381; 22.040 0.016
UCEIS
≤1 Ref
N1 0.849 −66.549; 68.247 0.980
All variables were included using the “enter”method; R2= 0.293; OR-Odds Ratio 95% CI –
95% conﬁdence interval.
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ATIs at the 6th/8th week was inversely correlated with IFX levels
14 days after the infusion (Spearman correlation coefﬁcient =
−0.295, p = 0.022) and IFX TLs (Spearman correlation coefﬁcient =
−0.480, p b 0.001).
To address the importance and interaction between ATIs and IFX-TLs
concerning clearance and AUC, these parameters were analyzed in pa-
tients stratiﬁed according to their status (positive or negative) regard-
ing clinical cut-offs of IFX TLs (3 μg/mL) and ATI concentration at the
6th/8th week (1.7 μg/mL) (Afonso et al., 2016; Vande Casteele et al.,
2015) (Table 2). Both clearance and AUC of the 8 weeks-regimen pa-
tients varied in a signiﬁcant fashion according to the ATI/IFX-deﬁned
patient group. These parameters were clearly associated with the pres-
ence of ATIs, as ATI positive patients had a higher clearance and conse-
quently a lower AUC. Concerning only ATI-negative patients, those that
were positive for IFX trough levels had a lower clearance and a higher
AUC.
As expected, clearance and ATI levels were correlated in a signiﬁcant
fashion (Spearman's coefﬁcient: 0.391, p = 0.005). A multiple regres-
sion analysis was made using clearance as the dependent variable and
considering patients' height, weight, albumin, UCEIS (as a proxy for in-
ﬂammatory burden) and ATI concentration. The multivariate model is
depicted in Table 3 and shows that ATI concentration is the only inde-
pendent predictor of clearance in these patients. Moreover, when
UCEIS was replaced by either the endoscopic Mayo score (stratiﬁed by
0 vs. ≥1 or ≤1 vs. N1) or by the Geboes index (stratiﬁed by b3.1 vs.
≥3.1), the results were similar (Supplementary Tables 1, 2 and 3).3.3. Pharmacodynamics
The patients' outcomes after the infusion cycle were evaluated in an
inclusive way, including the Mayo Global score assessment, the pres-
ence of endoscopic activity and histological inﬂammation, and the FC
levels (Table 4). Most patients (71.5%) had a global Mayo score equal
to or below 2, and 70.8%were considered to be in clinical remission (de-
ﬁned as global Mayo score below or equal to 2 and no individual sub-
score above 1). Endoscopic activity according to the UCEIS was absent
in 76.2% of the patients, whereas 60.3% and 82.5% did not exhibitmacro-
scopic lesions when the Mayo endoscopic score threshold was set at 0
and 1, respectively. Histological inﬂammation was present in 31.3% of
the patients, and 22.2 and 11.1% were above the FC threshold when
that was set at 150 and 250 μg/g, respectively. There were no signiﬁcant
differences between the outcomes of the patients under the 6-weeks'
and the 8-weeks' regimen (data not shown).
To test whether the IFX pharmacokinetic features were related to
patients' response in the cohort under study, patients were stratiﬁed
according their outcomes, and IFX TLs (Supplementary Table 4), ATIs
(Supplementary Table 5), AUC (Supplementary Tables 6 and 7) and clear-
ance (Supplementary Table 8)were compared betweenpositive andneg-
ative outcomes. However, there were no signiﬁcant differences to report.Table 2
Median and IQRs for clearance rates and AUC values stratiﬁed by ATI and IFX trough levels.
[ATI] cut-off = 1.7
[IFX] cut-off = 3
ATI−
IFX−
ATI−
IFX+
Clearance (mL/day) 228 [212.5–280.0] 164 [120–236]
N 8 23
AUC 6/6 weeks (μg·day/mL) 1388 [1206–1570] 1789 [1328–238
N 2 11
AUC 8/8 weeks (μg·day/mL) 1532 [1310–1617] 1821 [1603–230
N 6 14
a Kruskall Wallis test.3.4. Therapeutic Escalation
A total of 60 patients were re-evaluated to detect whether a thera-
peutic escalation was required later in their follow-up (ﬁve patients of
the initial cohort were lost to follow up). Overall, 10 patients escalated,
and the time spent from initial assessment to escalationwas, inmedian,
15.00 months (IQR: 8.00–20.00). To test whether the IFX pharmacoki-
netic features assessed previously were related to patients' escalation,
values of IFX TLs, ATIs, AUC and clearance were compared between pa-
tients with or without the need to escalate their therapy (Fig. 2). Pa-
tients are undistinguishable based on IFX TLs, clearance and AUC.
However, there is a clear trend for higher ATIs among patients who
later require therapeutic escalation.
Moreover, a Kaplan-Meyer analysis showed that patients with ATIs
levels above 1.7 μg/mL (Fig. 3A) and above 3 μg/mL (Fig. 3B) escalate
faster than those with lower levels, although only the 3 μg/mL cut-off
has statistical signiﬁcance. This analysis was expanded in order to in-
clude the biomarker FC, and the results show that patients with higher
levels of FC also escalate faster than their counterparts (Fig. 3C and D),
although signiﬁcant results are only present for the 250 μg/g cut-off.
Furthermore, the escalation was also faster when any of these condi-
tions (or both) were present (i.e., ATI above 3 μg/mL or FC above 250
μg/g), as compared to those patients whom had both values below the
cut-offs (Fig. 3E). Finally, this faster escalation is unrelated to the disease
severity from an histological and endoscopic perspective (Supplemen-
tary Fig. 1). In fact, a Cox regression considering all these parameters
shows that only ATI and FC levels are signiﬁcant for therapeutic escala-
tion: whereas an FC level above 250 μg/g has an HR (hazard ratio) of
escalating of 9.309, an ATI level below 3 μg/mL has an HR of 0.119
(Table 5). These values are maintained irrespective of whether the
endoscopic Mayo score cut-off was placed at 1 or 2.4. Discussion
The success of IFX in the treatment of many UC patients, material-
ized in a decrease of the number of surgeries and hospitalizations and
an increase in these patients' quality of life, is overshadowed by the no-ATI+
IFX−
ATI+
IFX+
p-Valuea
323.5 [252–360] 228.5 [168–327.5] b0.001
14 4
9] 826 [468–1199] 1448 [1186–2055] 0.071
3 3
2] 1090 [991–1479] 1426 [1426–1426] 0.004
12 1
Table 4
Outcomes at 6/8 weeks post-infusion.
n %
Global mayo score
1 36 55.4
2 10 16.1
3 6 9.7
4 2 3.2
5 5 4.8
6 2 3.2
7 1 1.6
8 1 1.6
11 1 1.6
Remission = no 19 29.2
Remission = yes 46 70.8
Endoscopic mayo score
0 38 60.3
≥1 25 39.7
≤1 52 82.5
N1 11 17.5
UCEIS
≤1 48 76.2
N1 15 23.8
Histology (Geboes score)
b3.1 44 68.8
≥3.1 20 31.3
FC (at 6/8 weeks) (μg/g)
b150 49 77.8
≥150 14 22.2
b250 56 88.9
≥250 7 11.1
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pharmacokinetics, pharmacodynamics and disease outcomes – includ-
ing the biomarker FC – were closely monitored during one IFX infusion
cycle in a population of clinically-stable UC patients.
The values of IFX TLs, AUC and clearance reported in this study were
within the range of those previously described in different studies and
clinical trials (Fasanmade et al., 2009; Brandse et al., 2016; Paserchia,
1999; Anon, n.d.). Interestingly, the different IFX regimens had similar
AUCs and clearance values, but could be distinguished based on their
IFX TLs, which were signiﬁcantly higher in the shorter regimen.Fig. 2. Relationship between therapeutic escalation episodes and theShortening the infusion interval is a commonly used strategy to intensi-
fy IFX therapy, shown to be superior or, at least, equivalent to the in-
crease of IFX dosage in LOR (Katz et al., 2012; St Clair et al., 2002). As
in the ATTRACT study, our results show that a shorter interval is associ-
atedwith higher IFX TLs (St Clair et al., 2002).Moreover, this increase in
IFX TLs - even without a concomitant increase in the IFX AUC - was suf-
ﬁcient for patients who suffered a LOR in the 8-weeks regimen regain
response to IFX. In fact, their outcomes were similar to those experi-
enced by the patients that remained in the 8-weeks' regimen.
Interestingly, ATIs levelswere the only signiﬁcant factor affecting IFX
clearance in this cohort. One can hypothesize that variables that affect
clearance in more severely ill patients (such as albumin, height, weight
and inﬂammatory burden) are not signiﬁcant in the population ad-
dressed in this study, whichwas constituted by patients in a stable con-
dition. Therefore, the presence of ATIs seems to be the main factor
affecting IFX availability, although these results worth a conﬁrmation
on a larger population.
The analysis of the cohort outcomes and disease indicators show
that, despite being classiﬁed as in remission according to the Montreal
classiﬁcation, a considerable proportion of patients still has endoscopic
lesions and a relatively high inﬂammatory burden. Interestingly, neither
IFX TLs, AUC, clearance nor ATI concentrationswere able to differentiate
patients with positive and negative outcomes. IFX TLs are considered to
be particularly useful for this: in fact, a search through the literature
shows that IFX TLs are many times used to monitor this drug on a ther-
apeutic scenario, and different authors have found signiﬁcant differ-
ences between IFX TLs in responders and non-responders, many times
using cut-off values close to the one used in this study (3 μg/mL), as de-
scribed by Silva-Ferreira et al. and references included (Silva-Ferreira et
al., 2016). Our analysis, however, suggest that these differences are ab-
sent or undiscernible when assessing clinically-stable and asymptomat-
ic patients.
We have then analyzed whether the pharmacokinetic proﬁle of
these patients could be used to evaluate their long-term risk of requir-
ing therapeutic escalation. Interestingly, there was a clear and signiﬁ-
cant trend for patients with higher ATI levels to need therapeutic
escalation later on their lives. Moreover, a cut-off of 3 μg/mL could be
statistically associated with the requirement of therapeutic escalation.IFX TLs (A), IFX AUC (B), ATI levels (C) and ATI clearance (D).
Fig. 3.Kaplan-Meyer survival curves for time to therapeutic escalation of: ATI levels using a cut-off of 1.7 μg/ml (A) or 3 μg/ml (B); FC levels using a cut-off of 150 μg/g (C) or 250 μg/g (D);
ATI levels above 3 μg/ml or FC levels above 250 μg/g (E).
128 F. Magro et al. / EBioMedicine 21 (2017) 123–130These results concurwith the data published previously by Edlund et al.,
who have shown that the presence of ATIs in Crohn's disease (CD) pa-
tients, irrespective of their concentration, eventually leads to a drop in
IFX levels to values below a critically minimum concentration (Edlundet al., 2016). Moreover, Ungar et al. have shown that ATI development
often precedes the onset of a clinical ﬂare (Ungar et al., 2014).
Additionally, a similar analysis including the FC levels has shown
that values above 250 μg/g are also signiﬁcantly associated with the
Table 5
Multi-variate Cox regression to therapeutic escalation.
p-Value HR 95% CI
IFX TLs 0.771 1.021 0.887 1.176
FC (ref: b250 μg/g) 0.018 9.309 1.455 59.561
ATIs (ref: N3 μg/mL) 0.010 0.119 0.024 0.594
Geboes index (ref: b3.1) 0.602 0.648 0.127 3.301
Mayo endoscopic score (ref: 0) 0.851 1.151 0.265 5.008
IFX TLs 0.774 1.020 0.889 1.171
FC (ref: b250 μg/g) 0.019 9.036 1.445 56.511
ATIs (ref: N3 μg/mL) 0.009 0.119 0.024 0.592
Geboes index (ref: b3.1) 0.575 0.619 0.116 3.310
Mayo endoscopic score (ref: ≤1) 0.772 1.318 0.204 8.530
HR- Hazard Ratio; 95% CI-95% conﬁdence interval.
129F. Magro et al. / EBioMedicine 21 (2017) 123–130requirement of therapeutic escalation. Such a relationship has been sug-
gested before by Burri et al., who claimed that changes of FC levels be-
tween measurements were related to therapeutic escalation (Burri et
al., 2015). From a different angle but supporting the same core idea,
Papamichael et al. have recently shown that the risk of relapse after
IFX de-escalation in CDpatients in composite deep remission is relative-
ly low when FC levels are maintained within the normal range
(Papamichael et al., 2016). Moreover, the results of a meta-analysis in-
cluding six different studies suggest that FC is useful to predict relapses
in quiescent UC and CD patients (Mao et al., 2012).
The simultaneous analysis of ATI and FC levels shows that the ther-
apeutic escalation is associated to high values of either these variables.
Importantly, their impact in the need of a future therapeutic escalation
is independent of the disease severity, as is shown by the fact that nei-
ther histological score nor endoscopic lesions are signiﬁcant variables
in this context. A combination of a biomarker and ATIs levels to predict
disease developmenthas been shownbefore: in fact, C-reactive proteins
levels combined with IFX-TLs and ATI stability were shown to predict
LOR in IBD patients (Roblin et al., 2015). Our results, together with the
literature, suggest that high levels of ATIs and FC found in otherwise sta-
ble UC patients may indicate a future disease ﬂare and its consequent
therapeutic escalation. These ﬁndings have some important clinical im-
plications: TDMon stable patients is useful if ATI levels are included and
should be performed alongside with FC determination: the presence of
elevated ATIs of FC levels – even in the absence of clinical symptoms –
should alert the physician to act in order to prevent future therapeutic
escalations.
This study has several strengths that should be noticed, namely
its prospective design with a systematic and multidimensional eval-
uation of the therapeutic response: endoscopic, histological and clin-
ical data was retrieved, in parallel with the quantiﬁcation of a
biomarker. Nevertheless, there were also a few limitations that
should be taken into consideration: the inclusion of a single infusion
cycle and the fact that we have not taken into account the amount of
IFX lost through the feces.
In short, this study explores the IFX pharmacokinetics and the utility
of drug and disease monitoring among UC patients in remission. Our
ﬁndings show that, in these patients, IFX clearance is mainly related to
the presence of ATIs. Moreover, and irrespective of the IFX regimen,
IFX TLs, AUC, clearance and ATI concentration are unable to differentiate
patients according to their outcome. Conversely, high ATI levels are sig-
niﬁcantly associated with the long-term need to undergo therapeutic
escalation, as are FC levels above 250 μg/g. Therefore, the usefulness of
TDM in clinically-stable UC patients relies on the possibility of avoiding
future disease progression that can be predicted based on the ATI levels.
Moreover, the monitoring of FC should also be carried out in these pa-
tients, as this biomarker is also increased in patients that eventually
need to undergo a therapeutic escalation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.06.004.Funding Sources
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